 |
This is a list of chages to the website.
You can Subscribe to our RSS FEED:  ,
which delivers brain tumor news and additions
to the website via RSS.
(Click HERE for
details on RSS.)
Displaying items 26 to 50 of about 4182
Previous 25 Next 25
|
|
|
|
|
|
|
Website Changes
|
|
|
|
04/21/2013 |
|
IBTA E NEWS APRIL 2013
|
|
|
|
|
|
04/20/2013 |
|
Final arrangements: Hitting the digital dead man`s switch
|
|
|
|
|
|
|
04/19/2013 |
|
NW Bio Announces That Another Brain Cancer Patient From Phase I/II DCVax(R)-L Trials Has Surpassed Ten-Year Cancer-Free Survival
|
|
|
|
|
|
04/19/2013 |
|
National Walk To End Brain Tumors
|
|
|
|
|
|
|
04/17/2013 |
|
The impact of improved treatment strategies on overall survival in glioblastoma patients.
|
|
|
|
|
|
04/12/2013 |
|
Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience.
|
|
|
|
|
|
|
04/12/2013 |
|
J Neurooncol. 2013 Apr 6. [Epub ahead of print]
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Iacovelli R, Burattini L, Berardi R, Cascinu S.
Clinica di Oncologia Medica, AOU "Ospedali Riuniti", Università Politecnica delle Marche, via Tronto 10/A, 60100, Ancona, Italy, mattymo@alice.it.
Abstract
Fotemustine (FTM) is a common treatment option for glioblastoma patients refractory to temozolomide (TMZ). Although elderly patients represent a large component of glioblastoma population, the feasibility and the efficacy of second-line FTM are not available in those patients.We retrospectively analyzed the records of glioblastoma patients older than 65 years, receiving FTM at a dose of 70-100 mg/m2 of FTM every week for 3 consecutive weeks (induction phase) and then every 3 weeks (70-100 mg/m2), as second-line treatment.Between January 2004 and December 2011, 65 glioblastoma patients (median age, 70 years; range, 65-79 years) were eligible for this analysis. Sixty-five patients received a total of 364 FTM cycles, with a median of 4 cycles for each patient. After induction, we observed 1 complete response (1.5 %), 12 partial responses (18.5 %), 18 stable diseases (27.7 %), and 34 patients` progressions (47.7 %). Disease control rate was 43.1 %. Median survival from the beginning of FTM therapy was 7.1 months, while the median progression-free survival was 4.2 months, and the 6-months progression free survival rate was 35.4 %. The most relevant grade 3-4 toxicity events were thrombocytopenia (15.3 %) and neutropenia (9.2 %). In the univariate and multivariate analysis, time from radiotherapy to FTM, number of TMZ and FTM cycles and disease control resulted independent prognostic factors.This study showed that FTM is a valuable therapeutic option for elderly glioblastoma patients, with a safe toxicity profile.
PMID: 23564276 [PubMed - as supplied by publisher]
|
|
|
|
|
|
04/12/2013 |
|
Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma.
|
|
|
|
|
|
|
04/12/2013 |
|
UCLA 13th Annual Brain Tumor Conference - For patients and families
|
|
|
|
|
|
04/12/2013 |
|
Ninth Surviving Brain Tumors Awareness Event—Cleveland
|
|
|
|
|
|
|
04/10/2013 |
|
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
|
|
|
|
|
|
04/10/2013 |
|
Radiation therapy new cancer cure
|
|
|
|
|
|
|
04/08/2013 |
|
Feds to cut Medicare payments for cancer-fighting Gamma Knife, thanks to Congress
|
|
|
|
|
|
03/31/2013 |
|
National Walk To End Brain Tumors - New Locations!
|
|
|
|
|
|
|
03/29/2013 |
|
Cancer Drug That Shrinks All Tumors Set To Begin Human Clinical Trials
|
|
|
|
|
|
03/27/2013 |
|
Musella Foundation Copay assistance program is now closed
|
|
|
|
|
|
|
03/27/2013 |
|
Device tested to treat aggressive brain tumors
|
|
|
|
|
|
03/26/2013 |
|
IFRT offers viable alternative to WBRT
|
|
|
|
|
|
|
03/24/2013 |
|
NY Yankees Fundraiser June 21!
|
|
|
|
|
|
03/24/2013 |
|
Diazepam (Valium)( Inhibits Proliferation of Human Glioblastoma Cells Through Triggering a G0/G1 Cell Cycle Arrest.
|
|
|
|
|
|
|
03/24/2013 |
|
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.
|
|
|
|
|
|
03/24/2013 |
|
Treatment outcome and prognostic factors of adult glioblastoma multiforme.
|
|
|
|
|
|
|
03/20/2013 |
|
New Trial: Phase I/II Trial of Repeated Superselective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme
|
|
|
|
|
|
03/13/2013 |
|
Body fat may help destroy brain cancer cells
|
|
|
|
|
|
|
03/13/2013 |
|
IBTA E News March 2013
|
|
|
|
|
|
|
|
